DOSSIER · 13F-HR · Q1 2026

Kynam Capital Management, LP

$1.6B in tracked AUM across 39 positions as of Q1 2026.

KC
CIK 0001907884 · last filed Mar 31, 2026
Total AUM
$1.6B
as of Q1 2026
Holdings
39
positions
Whale Score
70
70
strong
Activity
no data
changes this Q
AI Analysis · Q1 2026

Portfolio Overview

Kynam Capital Management's 13F filing for the period ending September 30, 2025, reveals a concentrated, high-conviction investment strategy focused entirely on the healthcare sector. The firm saw substantial growth in assets under management (AUM), with the total portfolio value increasing by 28.6% from approximately $928.82 million to $1.19 billion. Despite the significant capital inflow or appreciation, the fund maintains a relatively compact portfolio of 27 holdings.

...

Key Holdings

The portfolio is dominated by mid-to-large cap biotechnology companies, with the top five positions all representing double-digit percentage allocations.

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight
01
SNDX
SYNDAX PHARMACEUTICALS INC
$188M8.1M11.6%
02
CLDX
CELLDEX THERAPEUTICS INC NEW
$185M5.8M11.4%
03
PCVX
VAXCYTE INC
$170M2.9M10.5%
04
COGT
COGENT BIOSCIENCES INC
$155M4.0M9.6%
05
VERA
VERA THERAPEUTICS INC
$137M3.4M8.4%
06
BEAM
BEAM THERAPEUTICS INC
$88M3.7M5.4%
07
TVTX
TRAVERE THERAPEUTICS INC
$72M2.4M4.4%
08
CTMX
CYTOMX THERAPEUTICS INC.
$71M15.0M4.4%
09
BCRX
BIOCRYST PHARMACEUTICALS INC
$54M5.7M3.3%
10
VRDN
VIRIDIAN THERAPEUTICS INC
$46M2.3M2.8%

Filing history

2026Q1Mar 31
$1.6B 3.6%
39 positionsView →
2025Q4Dec 31
$1.6B 31.1%
37 positionsView →
2025Q3Sep 30
$1.2B 28.6%
27 positionsView →
2025Q2Jun 30
$929M 6.8%
31 positionsLocked
2025Q1Mar 31
$870M 48.6%
23 positionsLocked
2024Q4Dec 31
$1.7B 29.7%
30 positionsLocked
2024Q3Sep 30
$1.3B 0.6%
25 positionsLocked
2024Q2Jun 30
$1.3B 35.7%
26 positionsLocked
2024Q1Mar 31
$955M 5.9%
23 positionsLocked
2023Q4Dec 31
$903M 47.6%
24 positionsLocked
2023Q3Sep 30
$611M 15.9%
30 positionsLocked
2023Q2Jun 30
$727M 6.1%
26 positionsLocked
Showing 12 of 18